ASSESSING INTERSTITIAL PNEUMONIA IN ATHLETES WITH LYMPHOMA: CLINICAL FEATURES, TREATMENT STRATEGIES, AND PROGNOSTIC IMPLICATIONS

Abstract

Objectives: This study aims to elucidate the clinical characteristics, effective treatment modalities, and prognostic factors of chemotherapy-induced interstitial pneumonia (IP) in athletes with lymphoma, emphasizing the unique considerations necessary for this population. Methods: We conducted a retrospective analysis of 38 lymphoma patients who developed IP following chemotherapy. Data on clinical symptoms, laboratory findings, treatment responses, and recovery timelines were collected and analyzed to understand the progression and management of IP in this specific group. Results: Among the patients, a significant proportion (73.7%) were diagnosed with diffuse large B-cell lymphoma (DLBCL). Common symptoms included fever (73.7%) and dyspnea (55.3%), while 13.1% were asymptomatic. Laboratory analyses showed a notable decrease in absolute lymphocyte count (ALC) and albumin levels, and an increase in C-reactive protein (CRP), indicating an inflammatory response. Recovery was achieved in 36 patients with a median duration of 20 days. Factors such as poor performance status (ECOG PS ≥2), presence of fever or dyspnea, and positive respiratory cultures were associated with prolonged recovery. Lower ALC and higher CRP levels correlated with extended hospital stays. Conclusions: In athletes with lymphoma, factors like performance status, presence of typical IP symptoms, and specific laboratory markers are crucial in predicting the recovery trajectory from chemotherapy-induced IP. Understanding these can guide tailored interventions to manage IP effectively in athletes, ensuring quicker recovery and minimal disruption to their training and competitive schedules. Future studies should focus on preventive measures and early intervention strategies to optimize outcomes for this population.